Organon & Co. (OGN)
Health Care1 article
Price chart
Organon & Co. (OGN) overview
Organon is a women’s-health-focused pharmaceutical company spun off from Merck. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Organon & Co. trades on the NYSE under the ticker symbol OGN. As of the most recent market data, the stock was priced around $13.52, up 0.22% on the session, giving Organon & Co. a market capitalization of roughly $3.55B.
Over the past 52 weeks, OGN has traded between $5.69 and $13.60. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 14.5, a common gauge of how richly the market prices the company's earnings. Organon & Co. also pays a dividend, currently yielding around 59.00%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch OGN
As one of the larger companies in the Health Care sector, Organon & Co. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch OGN for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest OGN news
Organon (OGN) Surges 39% on $12 Billion Merger Speculation
Organon & Co. (OGN) experienced a significant increase of 38.8% week-on-week following reports of a potential $12 billion acquisition by Sun Pharmaceutical Industries. No official confirmation has been issued regarding the merger. Additionally, Organon reported a decreased net income of 78% to $187 million in 2024, with revenues down 3% to $6.2 billion. In the fourth quarter, the company recorded a net loss of $205 million, compared to a net income of $109 million the previous year, while quarterly revenues also declined by 5.3% to $1.5 billion.
Read More: Organon (OGN) Surges 39% on $12 Billion Merger SpeculationMore Health Care stocks
Frequently asked questions
Is Organon & Co. in the S&P 500?
Yes. Organon & Co. (OGN) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is OGN in?
Organon & Co. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest OGN news?
This page collects recent Organon & Co. (OGN) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Organon & Co.'s stock price?
As of the most recent market data, Organon & Co. (OGN) traded at approximately $13.52. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Organon & Co.'s market cap?
Organon & Co. has a market capitalization of roughly $3.55B, based on its most recent share price and shares outstanding.
What is OGN's P/E ratio?
OGN trades at a trailing price-to-earnings ratio of about 14.5. The P/E ratio compares a company's share price to its earnings per share.